FP 1039

Drug Profile

FP 1039

Alternative Names: Fibroblast growth factor ligand trap; FP-1039; GSK 3052230; HGS 1036

Latest Information Update: 22 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Mesothelioma; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Nov 2017 FP 1039 is still in phase I trials for Non-small cell lung cancer (Combination therapy, Late-stage disease) and Mesothelioma (Combination therapy, Late-stage disease) in United Kingdom, Belgium, Denmark, France, the Netherlands, Spain, Russia and USA (NCT01868022)
  • 06 Nov 2017 FP 1039 is available for licensing as of 06 Nov 2017. http://www.fiveprime.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top